BERRUTI, ALFREDO
 Distribuzione geografica
Continente #
NA - Nord America 31.003
AS - Asia 13.396
EU - Europa 10.160
SA - Sud America 3.316
AF - Africa 260
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 18
Totale 58.178
Nazione #
US - Stati Uniti d'America 30.625
SG - Singapore 4.789
CN - Cina 4.088
BR - Brasile 2.801
UA - Ucraina 2.759
HK - Hong Kong 1.764
DE - Germania 1.539
IT - Italia 1.305
VN - Vietnam 1.027
PL - Polonia 958
RU - Federazione Russa 693
GB - Regno Unito 649
FI - Finlandia 629
TR - Turchia 594
IE - Irlanda 515
IN - India 273
FR - Francia 228
AR - Argentina 206
EE - Estonia 191
CA - Canada 185
BD - Bangladesh 183
SE - Svezia 143
ID - Indonesia 133
MX - Messico 118
CZ - Repubblica Ceca 113
ZA - Sudafrica 108
IQ - Iraq 94
NL - Olanda 89
EC - Ecuador 87
JP - Giappone 84
ES - Italia 74
AT - Austria 64
BE - Belgio 53
SA - Arabia Saudita 50
PK - Pakistan 46
VE - Venezuela 44
PY - Paraguay 43
UZ - Uzbekistan 43
MA - Marocco 41
CO - Colombia 40
CL - Cile 37
AE - Emirati Arabi Uniti 31
EG - Egitto 29
LT - Lituania 26
KE - Kenya 23
UY - Uruguay 22
AU - Australia 21
CH - Svizzera 21
KZ - Kazakistan 21
AZ - Azerbaigian 20
DZ - Algeria 20
PE - Perù 20
JM - Giamaica 19
KR - Corea 17
EU - Europa 16
JO - Giordania 16
IL - Israele 15
LB - Libano 15
PT - Portogallo 15
CR - Costa Rica 14
TN - Tunisia 14
AL - Albania 13
DK - Danimarca 13
NP - Nepal 12
PA - Panama 12
BO - Bolivia 11
BG - Bulgaria 10
IR - Iran 10
RO - Romania 9
KG - Kirghizistan 8
LV - Lettonia 8
TT - Trinidad e Tobago 8
HN - Honduras 7
PS - Palestinian Territory 7
TW - Taiwan 7
BB - Barbados 6
ET - Etiopia 6
BH - Bahrain 5
DO - Repubblica Dominicana 5
HU - Ungheria 5
MD - Moldavia 5
MK - Macedonia 5
MU - Mauritius 5
NO - Norvegia 5
SK - Slovacchia (Repubblica Slovacca) 5
AM - Armenia 4
CY - Cipro 4
GE - Georgia 4
GR - Grecia 4
KW - Kuwait 4
LK - Sri Lanka 4
OM - Oman 4
TH - Thailandia 4
GY - Guiana 3
IS - Islanda 3
LA - Repubblica Popolare Democratica del Laos 3
MY - Malesia 3
NZ - Nuova Zelanda 3
PH - Filippine 3
SN - Senegal 3
Totale 58.140
Città #
Fairfield 4.232
Woodbridge 3.240
Ashburn 2.531
Houston 2.217
Singapore 2.163
Jacksonville 1.880
Hong Kong 1.757
Seattle 1.742
Cambridge 1.594
Wilmington 1.379
Ann Arbor 1.362
Beijing 1.201
Warsaw 946
Princeton 879
Chandler 728
New York 716
Los Angeles 585
Dallas 536
Chicago 493
Dublin 472
Nanjing 471
Istanbul 466
Helsinki 407
Ho Chi Minh City 361
The Dalles 332
Munich 301
Buffalo 250
Brescia 246
Des Moines 230
Redondo Beach 226
São Paulo 204
Dearborn 199
Moscow 198
Tallinn 191
Nanchang 188
Salt Lake City 188
San Diego 184
Hanoi 181
Shanghai 157
Changsha 151
Milan 146
Boardman 141
Shenyang 140
Hebei 133
San Francisco 131
London 127
Turku 116
Tianjin 101
Jinan 93
Rio de Janeiro 88
Tampa 86
Jakarta 85
Brno 80
Dong Ket 80
Elk Grove Village 80
Brooklyn 73
Secaucus 72
Nuremberg 70
Santa Clara 70
Jiaxing 69
Stockholm 68
Belo Horizonte 61
Tokyo 61
Dalmine 60
Hangzhou 58
Johannesburg 57
Romola 57
Orange 56
Brasília 55
Kunming 54
Verona 54
Phoenix 53
Brussels 52
Lancaster 52
Orem 52
Poplar 52
Kocaeli 51
Toronto 49
Zhengzhou 49
Boston 47
Montreal 47
Rome 47
Atlanta 46
Guangzhou 45
Da Nang 43
Sterling 43
Curitiba 42
Denver 41
Haiphong 41
Washington 40
Chennai 39
Tashkent 39
Lappeenranta 38
Porto Alegre 38
West Jordan 38
Campinas 37
Mexico City 37
Biên Hòa 36
Baghdad 35
Ningbo 34
Totale 39.669
Nome #
Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer 765
Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. 361
GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity 282
Adrenocortical carcinoma xenograft in zebrafish embryos as model to study the in vivo cytotoxicity of abiraterone acetate 277
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 254
Excess of second tumors in denosumab-treated patients: A metabolic hypothesis 234
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study 233
Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma 232
Eight‐week interval in flushing and locking port‐a‐cath in cancer patients: A single‐institution experience and systematic review 231
Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. 228
In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆ 225
Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures 224
Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review 221
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† 219
IN VITRO ANTITUMOR ACTIVITY OF PROGESTERONE IN HUMAN ADRENOCORTICAL CARCINOMA 207
Pros-IT CNR: an Italian prostate cancer monitoring project 206
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 203
Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy 203
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case 201
Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma 200
Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy 198
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells 197
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials 196
Immunotherapy failure in adrenocortical cancer: where next? 195
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma 194
Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy 194
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement 192
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. 186
The guanine nucleotide exchange factor VAV2 as a new prognostic parameter in adrenocortical carcinoma 182
Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells 178
Regression of advanced neuroendocrine tumors among patients receiving placebo 178
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents 178
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options 178
Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity 177
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer 175
Should Adjuvant Weekly Paclitaxel Be Considered Less Efficacious Than Anthracyclines Plus Cyclophosphamide for Lower Risk Patients With Early-Stage Breast Cancer? 174
Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study 173
Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy 172
Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria 172
Palbociclib inhibits proliferation of human adrenocortical tumor cells 171
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines 170
Biological bases of radical prostatectomy in the management of prostate cancer patients with oligometastatic disease 170
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer 169
Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis 167
Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report 167
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer 164
Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method 164
A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report 164
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 163
CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs) 163
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies. 163
Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement 162
Adjuvant bisphosphonates in patients with breast cancer: Does the potency matter? 162
Analysis of Circulating Tumor Cells in Prostate Cancer Patients at PSA Recurrence and Review of the Literature 162
Osimertinib in EGFR Mutation–Positive Advanced NSCLC 162
When should everolimus be administered in the natural history of pancreatic neuroendocrine tumors? 161
Antineoplastic Activity of Artemisinin in Adrenocortical Carcinoma 161
Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis 160
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) 159
Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. 159
828PBONE METASTASES FROM RCC ARE NOT ALWAYS ASSOCIATED WITH A POOR PROGNOSIS 159
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. 158
Serum vitamin D and prostate cancer prognosis: The story continues 157
The Circadian Rhythm of Breakthrough Pain Episodes in Terminally-ill Cancer Patients 157
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 157
Effect of primary letrozole treatment on tumor expression of mTOR and HIF-1α and relation to clinical response 157
Exemestane with ovarian suppression in premenopausal breast cancer. 157
Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice 156
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature 155
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 154
Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer? 153
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports 153
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 153
A current perspective on treatment of adrenocortical carcinoma 152
Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines? 152
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. 150
Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients 149
Gonadal function in male patients with metastatic renal cell cancer treated with sunitinib: Effects of testosterone replacement on quality of life. 148
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma 148
Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge. 148
Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report 145
An unusual case of a well-differentiated neuroendocrine tumour of the ileum with peritoneal carcinomatosis: A case report 145
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME) 145
Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference 145
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma 144
Molecular target agents in adrenocortical carcinoma: rationale and difficulties in trial design 143
Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy worse radical cystectomy outcomes in frails 143
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study 142
IFN-α in advanced well-differentiated neuroendocrine tumors: The neglected drug? 142
Aspergillosis superinfection as a cause of death of crizotinib-induced interstitial lung disease successfully treated with high-dose corticosteroid therapy 140
The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures 140
MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects 140
Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases. 139
Abiraterone and increased survival in metastatic prostate cancer 139
Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance 139
Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study 138
Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. 136
The pathological diagnosis of neuroendocrine tumors: Common questions and tentative answers 136
Prognostic factors in patients receiving third-line targeted therapy for metastatic renal cell carcinoma. 135
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): An European Network for the Study of Adrenal Tumor (ENSAT) study 135
Totale 18.022
Categoria #
all - tutte 292.889
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 292.889


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.783 0 0 0 0 0 777 392 786 619 1.174 650 385
2021/20223.503 274 702 93 213 50 182 214 234 194 349 267 731
2022/20232.586 497 83 74 178 191 712 10 212 347 44 115 123
2023/20243.948 180 96 316 217 207 696 109 145 1.039 118 48 777
2024/202510.895 98 74 98 1.510 1.168 737 591 293 1.088 803 2.697 1.738
2025/202611.799 1.636 2.770 1.934 3.138 1.553 768 0 0 0 0 0 0
Totale 59.195